

## DAFTAR PUSTAKA

1. Cacho-Díaz B, Spínola-Maróño H, Mendoza-Olivas LG, Monroy-Sosa A, Reyes-Soto G, Arrieta O. Association of neurologic manifestations and CEA levels with the diagnosis of brain metastases in lung cancer patients. *Clin Transl Oncol* [Internet]. 2019;21(11):1538–42. Available from: <https://doi.org/10.1007/s12094-019-02086-y>
2. Souza VGP, de Araújo RP, Santesso MR, Seneda AL, Minutentag IW, Felix TF, et al. Advances in the Molecular Landscape of Lung Cancer Brain Metastasis. *Cancers (Basel)*. 2023;15(3).
3. The Lancet Regional Health-Southeast Asia. Cancer in southeast Asia: can we do better? *Lancet Reg Heal Southeast Asia*. 2023;12:100216.
4. Suraya A, Nowak D, Sulistomo AW, Icksan AG, Berger U, Syahrudin E, et al. Excess risk of lung cancer among agriculture and construction workers in Indonesia. *Ann Glob Heal*. 2021;87(1):1–14.
5. Zappa C, Mousa SA. Non-small cell lung cancer: Current treatment and future advances. *Transl Lung Cancer Res*. 2016;5(3):288–300.
6. Yao Y, Fareed R, Zafar A, Saleem K, Huang T, Duan Y, et al. State-of-the-art combination treatment strategies for advanced stage non-small cell lung cancer. *Front Oncol* [Internet]. 2022 Aug 1;12. Available from: <https://www.frontiersin.org/articles/10.3389/fonc.2022.958505/full>
7. Sánchez-Ortega M, Carrera AC, Garrido A. Role of NRF2 in Lung Cancer. *Cells*. 2021 Jul;10(8):1879.
8. Singh A, Daemen A, Nickles D, Jeon S-M, Foreman O, Sudini K, et al. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes. *Clin Cancer Res* [Internet]. 2021 Feb 1;27(3):877–88. from: <https://aacrjournals.org/clincancerres/article/27/3/877/266009/NRF2-Activation-Promotes-Aggressive-Lung-Cancer>
9. Wang Y, Q, Xu L, Wang G, Chen L, Li C, Jiang X, et al. Prognostic and clinicopathological significance of NRF2 expression in non-small cell cancer: A meta-analysis. Vranic S, editor. *PLoS One* [Internet]. 2020



- Nov 13;15(11):e0241241. Available from: <https://dx.plos.org/10.1371/journal.pone.0241241>
10. Santoso A, Kikuchi T, Tode N, Hirano T, Komatsu R, Damayanti T, et al. Syndecan 4 mediates Nrf2-dependent expansion of bronchiolar progenitors that protect against lung inflammation. *Mol Ther*. 2016;24(1):41–52.
  11. Zhao J, Lin X, Meng D, Zeng L, Zhuang R, Huang S, et al. Nrf2 Mediates Metabolic Reprogramming in Non-Small Cell Lung Cancer. *Front Oncol* [Internet]. 2020 Nov 26;10. Available from: <https://www.frontiersin.org/articles/10.3389/fonc.2020.578315/full>
  12. Kemenkes RI. PNPk Kanker Paru. Kementrian Kesehatan RI; 2023.
  13. Siddiqui F, Vaqar S, Siddiqui AH. Lung Cancer. *StatPearls* [Internet]; 2022.
  14. Clark SB, Alsubait S. Non-Small Cell Lung Cancer. *StatPearls* [Internet]; 2022.
  15. Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non-Small Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. *J Thorac Oncol*. 2015;10(7):974–984.
  16. Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, et al. Immune Cell Composition in Human Non-small Cell Lung Cancer. *Front Immunol*. 2018;9(February):3101.
  17. Nooreldeen R, Bach H. Current and Future Development in Lung Cancer Diagnosis. *Int J Mol Sci*. 2021 Aug;22(16):8661.
  18. Lemjabbar-Alaoui H, Hassan OU, Yang Y-W, Buchanan P. Lung cancer: Biology and treatment options. *Biochim Biophys Acta - Rev Cancer*. 2015 Dec;1856(2):189–210.
  19. Putzu C, Canova S, Paliogiannis P, Lobrano R, Sala L, Cortinovis DL, et al. Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment? *Cancers (Basel)*. 2023;15(3).
  20. Hwang KE, Kim HR. Response evaluation of chemotherapy for lung cancer. *Respir Dis (Seoul)*. 2017;80(2):136–42.



ke NA, Rupp ABA, Trimpop N, von Pawel J, Holdenrieder S. Soluble nobility group box 1 (Hmgb1) is a promising biomarker for prediction of

- therapy response and prognosis in advanced lung cancer patients. *Diagnostics*. 2021;11(2).
22. Cloer EW, Goldfarb D, Schrank TP, Weissman BE. NRF2 activation in cancer: from DNA to protein. *HHS Public Access*. 2020;79(5):889–98.
  23. Geismann C, Arlt A, Sebens S, Schäfer H. Cytoprotection “gone astray”: Nrf2 and its role in cancer. *Onco Targets Ther*. 2014;7:1497–518.
  24. Lignitto L, LeBoeuf SE, Homer H, Jiang S, Askenazi M, Karakousi TR, et al. Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1. *Cell*. 2019;178(2):316-329.e18.
  25. Koswara T, Iriawan J, Surya F. Karakteristik Karsinoma Paru Bukan Sel Kecil Dan Hasil Pemeriksaan Egfr Di Rsup Dr. Hasan Sadikin Periode Tahun 2018-2020. *Med Kartika J Kedokt dan Kesehatan*. 2022;5(Volume 5 No 2):150–61.
  26. Gkogkou P, Peponi E, Ntaskagiannis D, Murray S, Demou A, Sainis I, et al. E-Cadherin and Syndecan-1 Expression in Patients With Advanced Non-small Cell Lung Cancer Treated With Chemoradiotherapy. *In Vivo*. 2020;34(1):453–9.
  27. Fidler-Benaoudia MM, Torre LA, Bray F, Ferlay J, Jemal A. Lung cancer incidence in young women vs. young men: A systematic analysis in 40 countries. *Int J Cancer*. 2020;147(3):811–9.
  28. Putri A, Pratiwi SE, Musawaris RF. Characteristics of Lung Cancer Patients at Dr. Soedarso Hospital Pontianak from 2017 to 2019. *Indones J Cancer*. 2023;17(2):101.
  29. Tarigan SP, Soeroso NN, Tumanggor CAK, Gani S, Pradana A. Clinical profile of male patients with non-small cell lung cancer in Adam Malik General Hospital, Medan, Indonesia. *Open Access Maced J Med Sci*. 2019;7(16):2612–4.
  30. Jradi H. on the Circadian Pattern of Melatonin Report. *Ann Thorac Meedicine*. 2017;13(3):156–62.



, McGlynn KA, Nations JA, Shriver CD, Zhu K. Comorbidity and stage prognosis among lung cancer patients in the US military health system. *Am J Causes Control*. 2020;31(3):255–61.

32. Bhowmik S, Mohanto NC, Sarker D, Sorove AA. Incidence and Risk of Lung Cancer in Tuberculosis Patients, and Vice Versa: A Literature Review of the Last Decade. *Biomed Res Int.* 2022;2022.
33. Siddiqui F, Vaqar S, Siddiqui AH. Lung Cancer. In *Treasure Island (FL)*; 2024.
34. Biciușcă V, Popescu IAS, Trașcă DM, Olteanu M, Stan IS, Durand P, et al. Diagnosis of lung cancer by flexible fiberoptic bronchoscopy: a descriptive study. *Rom J Morphol Embryol.* 2022;63(2):369–81.
35. Rodríguez-Lara V, Ramírez-Tirado LA, Barrón F, Zatarain-Barrón ZL, Flores-Estrada D, Arrieta O. Characteristics of non-small cell lung cancer: Differences by sex and hormonal status in a Mexican population. *Salud Publica Mex.* 2019;61(3):265–75.
36. Isitmangil T, Isitmangil G, Budak Y, Aydilek R, Celenk MK. Comparison of serum and bronchoalveolar lavage fluid sialic acid levels between malignant and benign lung diseases. *BMC Pulm Med.* 2011;1:4.
37. Hogeia P, Tudorache E, Fira-Mladinescu O, Marc M, Velescu D, Manolescu D, et al. Serum and Bronchoalveolar Lavage Fluid Levels of Cytokines in Patients with Lung Cancer and Chronic Lung Disease: A Prospective Comparative Study. *J Pers Med.* 2023 Jun;13(6).
38. Zhang J, Liu K, Tang X, Wang XJ. Dysfunction of Nrf2-regulated cellular defence system and JNK activation induced by high dose of fly Ash particles are associated with pulmonary injury in mouse lungs. *Ecotoxicol Environ Saf* [Internet]. 2024;275:116239. Available from: <https://www.sciencedirect.com/science/article/pii/S0147651324003154>
39. Lin X, Cai Y, Zong C, Chen B, Shao D, Cui H, et al. Bronchoalveolar Lavage as Potential Diagnostic Specimens to Genetic Testing in Advanced Nonsmall Cell Lung Cancer. *Technol Cancer Res Treat.* 2023;22(88):1–9.
40. Pastor MD, Nogal A, Molina-Pinelo S, Meléndez R, Romero-Romero B, ano MD, et al. Identification of oxidative stress related proteins as markers for lung cancer and chronic obstructive pulmonary disease in hoalveolar lavage. *Int J Mol Sci.* 2019;14(2):3440–55.



41. Kalkanis A, Papadopoulos D, Testelmans D, Kopitopoulou A, Boeykens E, Wauters E. Bronchoalveolar Lavage Fluid-Isolated Biomarkers for the Diagnostic and Prognostic Assessment of Lung Cancer. *Diagnostics (Basel, Switzerland)*. 2022 Nov;12(12).
42. Xiang M, Feng J, Geng L, Yang Y, Dai C, Li J, et al. Sera total oxidant/antioxidant status in lung cancer patients. *Med (United States)*. 2019;98(37):1–6.
43. Lai YH, Chen WN, Hsu TC, Lin C, Tsao Y, Wu S. Overall survival prediction of non-small cell lung cancer by integrating microarray and clinical data with deep learning. *Sci Rep [Internet]*. 2020;10(1):1–11. Available from: <http://dx.doi.org/10.1038/s41598-020-61588->

